PRO 140 CD02 Study

- Significant viral load reduction for subjects treated with PRO 140, in comparison to placebo-treated subjects, was observed after a single SC injection.
- Subjects with ≥0.5 log10 copies/mL reduction:
  - 64% in the PRO 140 group
  - 23.08% in the placebo group
- PRO 140 also demonstrated the long-term ability to suppress viral load.
- Additionally, PRO 140 offers patients an alternative route of administration. The therapy can be self-administered subcutaneously on a weekly basis. This is expected to increase treatment compliance by eliminating the burden of daily pills or frequent clinic visits.
- A roll-over study, PRO 140 CD02-Extension, was designed to extend a subject's access to PRO 140 treatment when, in the opinion of the treating physician, PRO 140 was required to form a viable suppressive regimen.
- To date, 36 subjects have entered the extension study.